{"log_id": 5600863115314558594, "direction": 0, "words_result_num": 27, "words_result": [{"probability": {"variance": 0.023716, "average": 0.920663, "min": 0.429961}, "location": {"width": 864, "top": 109, "height": 42, "left": 185}, "words": "ST升高5×正常值上限(ULN)2或胆红素升高>3xULN,须停药且勿再使用本品(见药代动"}, {"probability": {"variance": 0.001216, "average": 0.97341, "min": 0.924087}, "location": {"width": 59, "top": 168, "height": 29, "left": 181}, "words": "力学)"}, {"probability": {"variance": 0.015771, "average": 0.943616, "min": 0.479878}, "location": {"width": 827, "top": 203, "height": 47, "left": 223}, "words": "严重肝功能损( (child-pugh C级患者不得使用本品另一项试验在8例基线严重肝功能损"}, {"probability": {"variance": 0.018114, "average": 0.942082, "min": 0.431591}, "location": {"width": 870, "top": 255, "height": 41, "left": 181}, "words": "害(Chd- -Pugh C级)受试者和8例肝功能正常的健康对照受试者中分析了阿比特龙的药物代谢"}, {"probability": {"variance": 0.014134, "average": 0.953263, "min": 0.355333}, "location": {"width": 873, "top": 301, "height": 42, "left": 183}, "words": "动力学。与肝功能正常的受试者相比基线严重肝功能损害受试者的阿比特龙全身暴露量(AUC"}, {"probability": {"variance": 0.011361, "average": 0.970223, "min": 0.519157}, "location": {"width": 410, "top": 357, "height": 31, "left": 184}, "words": "增加?倍,游离药物部分的暴露量增加2倍"}, {"probability": {"variance": 7.1e-05, "average": 0.985801, "min": 0.973886}, "location": {"width": 70, "top": 439, "height": 26, "left": 185}, "words": "肝毒性"}, {"probability": {"variance": 0.02074, "average": 0.920398, "min": 0.446318}, "location": {"width": 830, "top": 474, "height": 39, "left": 228}, "words": "对本晶治疗翔间发生肝毒性的思者(ALT和或AST>5XN或总胆红素>3XULN),应暂时中"}, {"probability": {"variance": 0.025184, "average": 0.912075, "min": 0.382017}, "location": {"width": 870, "top": 521, "height": 40, "left": 187}, "words": "断本品治疗并调整剂量见注意事项)。在肝功能水平恢复到基线水平或AST和AIT2SULN且"}, {"probability": {"variance": 0.005572, "average": 0.962775, "min": 0.706489}, "location": {"width": 870, "top": 567, "height": 42, "left": 191}, "words": "总胆红素≤15xULN后,可降低剂量至750mg每日1次再次治疗。对恢复治疗患者,至少每2"}, {"probability": {"variance": 0.0029, "average": 0.980909, "min": 0.718239}, "location": {"width": 572, "top": 620, "height": 32, "left": 190}, "words": "周监测次血清转氨酶和胆红素水平,3个月后每月监测1次"}, {"probability": {"variance": 0.001251, "average": 0.978592, "min": 0.827648}, "location": {"width": 829, "top": 656, "height": 47, "left": 232}, "words": "如果750mg每日1次给药时再次发生肝毒性,可在肝功能检查值恢复到基线水平或AST"}, {"probability": {"variance": 0.024999, "average": 0.912327, "min": 0.412219}, "location": {"width": 758, "top": 708, "height": 38, "left": 192}, "words": "和A2.5×LN并且总胆红素≤1.5ULN后,降低剂量至500mg每日工次再次治疗"}, {"probability": {"variance": 0.023043, "average": 0.912406, "min": 0.498306}, "location": {"width": 828, "top": 752, "height": 40, "left": 235}, "words": "如果500mg每日1次给药时再次发生肝毒性,须停药。尚不清楚在AST或ALT≥2XULN和"}, {"probability": {"variance": 0.014923, "average": 0.949312, "min": 0.47814}, "location": {"width": 518, "top": 804, "height": 33, "left": 189}, "words": "或胆红素≥10ULN患者中再次使用本品治疗的安全性"}, {"probability": {"variance": 2.7e-05, "average": 0.997132, "min": 0.980899}, "location": {"width": 281, "top": 897, "height": 30, "left": 196}, "words": "肾功能损害情况下的剂量调整"}, {"probability": {"variance": 0.008085, "average": 0.97028, "min": 0.509026}, "location": {"width": 826, "top": 937, "height": 37, "left": 239}, "words": "对肾功能损害患者,无需进行剂量调整【见药代动力学但在重度肾功能损害的前列腺癌"}, {"probability": {"variance": 0.01094, "average": 0.966664, "min": 0.513968}, "location": {"width": 429, "top": 988, "height": 30, "left": 198}, "words": "患者中尚无临床经验。此类患者建议谨慎使用"}, {"probability": {"variance": 0.009609, "average": 0.940163, "min": 0.694771}, "location": {"width": 384, "top": 1033, "height": 34, "left": 197}, "words": "合并使用强CYP3A4诱导剂时的剂量调整"}, {"probability": {"variance": 0.007952, "average": 0.954504, "min": 0.586789}, "location": {"width": 850, "top": 1073, "height": 42, "left": 242}, "words": "本品治疗期间避免合并使用强CYP3A4诱导剂(如苯妥英钠、卡马西平、利福乎、利福布N"}, {"probability": {"variance": 0.015652, "average": 0.935156, "min": 0.420902}, "location": {"width": 920, "top": 1110, "height": 52, "left": 200}, "words": "汀、利福喷丁、苯巴比妥虽然尚无关于接受强CYP3A4导剂治疗期间本品剂量调整的临床"}, {"probability": {"variance": 0.011496, "average": 0.950401, "min": 0.580601}, "location": {"width": 953, "top": 1158, "height": 50, "left": 202}, "words": "数据,但鉴于潜在的相互作用,如果必须合并使用强CYP3A4诱导剂,需在合并用药期间增加"}, {"probability": {"variance": 0.020122, "average": 0.920254, "min": 0.380627}, "location": {"width": 925, "top": 1213, "height": 39, "left": 205}, "words": "本品的绘药频率至每日2次【例如,从1000.m每日1次增至1000mg每日2次)在停止合"}, {"probability": {"variance": 0.024242, "average": 0.924683, "min": 0.350806}, "location": {"width": 943, "top": 1250, "height": 49, "left": 203}, "words": "并使用强CYP3A4导剂后,应将本品调整至原给药剂量和频率(现药物相互作用和药代动1"}, {"probability": {"variance": 0.012672, "average": 0.88404, "min": 0.771471}, "location": {"width": 28, "top": 1313, "height": 27, "left": 209}, "words": "学〕"}, {"probability": {"variance": 2.2e-05, "average": 0.995656, "min": 0.985495}, "location": {"width": 118, "top": 1389, "height": 28, "left": 216}, "words": "【不良反应】"}, {"probability": {"variance": 0.000172, "average": 0.989609, "min": 0.960876}, "location": {"width": 153, "top": 1440, "height": 30, "left": 210}, "words": "安全性特征概要"}], "language": 3}